FierceBiotech

Phase 3 GATTEX(R) (teduglutide) Data Highlight Potential New Treatment for Adults with Short Bowel Syndrome

NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), a specialty pharmaceutical company developing innovative therapeutics for rare gastrointestinal and endocrine disorders, today announced new data from STEPS 2 ...
Medscape

Teduglutide Reduces Parenteral Support Needs in Short Bowel

Teduglutide (Revestive, Nycomed/Takeda, in the European Union; Gattex, NPS Pharmaceuticals, in the United States) appears to reduce the need for parenteral support in patients with short bowel ...
Healio

Teduglutide improves stool outcomes in children with short bowel syndrome over 96 weeks

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Stool frequency and consistency improved over 96 weeks ...
Medindia

Side effect(s) of Teduglutide

Review the side-effects of Teduglutide as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of the ...
FierceBiotech

GATTEX(R) (teduglutide) Meets Primary Efficacy Endpoint in Phase 3 Pivotal Study in Patients with Adult Short Bowel Syndrome

BEDMINSTER, N.J., Jan 31, 2011 (BUSINESS WIRE) -- NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), a specialty pharmaceutical company developing innovative therapeutics for rare gastrointestinal and ...
AOL

FDA Approves Gattex® (teduglutide [rDNA Origin]) for Injection for the Treatment of Adult Short Bowe

BEDMINSTER, N.J.--(BUSINESS WIRE)-- NPS Pharmaceuticals, Inc. (NAS: NPSP) , a biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases ...
Europa Press

Revestive(R) (Teduglutide) Receives European Marketing Authorization for the Treatment of Adults With Short Bowel Syndro

- SBS is a rare and highly disabling condition that impacts patients' quality of life and can lead to serious life-threatening complications. - Teduglutide has received orphan drug designation for the ...
Business Wire

FDA Approves Updated Labeling for Gattex® (Teduglutide [rDNA origin]) for Injection to Include Long-Term Data | Business Wire

Gattex® (teduglutide [rDNA origin]) for injection for subcutaneous use is a novel, recombinant analog of human glucagon-like peptide 2, a protein involved in the rehabilitation of the intestinal ...
Medscape

Teduglutide for Short Bowel Given Positive Response in EU

June 27, 2012 — A novel peptide analogue, teduglutide (Revestive, Nycomed/Takeda), is the first medical treatment recommended for approval by the European Medicines Agency (EMA) for use in adults with ...
Nature

Teduglutide and gut function in patients with short-bowel syndrome

Short-bowel syndrome (SBS) patients with intestinal failure suffer from malabsorption and usually require long-term parenteral nutrition. It has been suggested that glucagon-like peptide 2 (GLP2), a ...
National Institute for Health and Care Excellence

Teduglutide for treating short bowel syndrome

There is a simple discount patient access scheme for teduglutide. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...
Business Wire

Phase 3 GATTEX® (teduglutide) Data Highlight Potential New Treatment for Adults with Short Bowel Syndrome

Professor Palle Bekker Jeppesen, M.D., University Hospital of Copenhagen, Denmark, presented results from a study designed to describe the effects of teduglutide when individual components such as ...